A forthcoming clinical trial will test the synergistic effects of Tocilizumab (anti-IL-6) and Atezolizumab (anti-PD-L1) in patients with NSCLC who have previously failed immune checkpoint blockade and are experiencing advanced or metastatic disease (NCT04691817). Here, IL6 is linked to non-small cell lung carcinoma.